Einleitung wieder einblenden

To Reduce the Use of Chemotherapy in Elderly Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

Datenbasis: WHO (Import vom 26.01.2020)
Geändert: 15.12.2019

Health conditions (Datenquelle: WHO)

Breast Cancer;Estrogen Receptor Positive Tumor;HER2-positive Breast Cancer

Interventions (Datenquelle: WHO)

Drug: Paclitaxel;Drug: Trastuzumab;Drug: Pertuzumab;Drug: Palbociclib;Drug: Letrozole

Inclusion/Exclusion Criteria (Datenquelle: WHO)

Inclusion Criteria:

- Histologically confirmed invasive breast cancer, with the following characteristics:

- Early breast cancer with tumor size >1 cm (as measured by at least one of the required
examination methods of clinical examination, mammography and ultrasonography); No
clinical evidence of regional lymph node metastasis (N0), or, nodal involvement
limited to clinically detectable metastasis to movable ipsilateral level I, II
axillary lymph node(s) (N1); No evidence of metastasis (M0).

- Female aged 65 years or older

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Primary tumor must have positive estrogen receptor (ER) =10%

- Primary tumor must be HER2-positive (by IHC and/or ISH)

- Baseline LVEF =55% measured by Echocardiography (preferred) or MUGA scan

- Normal hematologic status: Absolute neutrophil count =1500/mm3 (1.5 × 109/L);
Platelets =100 × 109/L; Hemoglobin =9 g/dL (=90 g/L).

- Normal renal function: serum creatinine =1.5 ULN

- Normal liver function: Serum total bilirubin =1.5 × upper limit of normal (ULN). In
the case of known Gilbert's syndrome, a higher serum total bilirubin (<2 × ULN) is
allowed; AST or ALT =2.5 × ULN; Alkaline phosphatase =2.5 × ULN.

- Written Informed Consent (IC) must be signed and dated by the patient and the
Investigator prior to randomization.

- The patient has been informed of and agrees to data transfer and handling, in
accordance with national data protection guidelines.

- The patient agrees in writing to make tumor (mandatory diagnostic core biopsy and
surgical specimen) available for submission for central pathology review and to
conduct translational studies as part of this protocol.

Exclusion Criteria:

- Tumor of any size with direct extension to the chest wall and/or to the skin
(ulceration or skin nodules) (T4 according to AJCC 8th edition cancer staging TNM)

- Inflammatory breast cancer

- Bilateral invasive breast cancer

- Received any prior treatment for primary invasive breast cancer

- Any active tumor of non-breast-cancer histology

- Any of the following in the previous 6 months: myocardial infarction, severe/unstable
angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade =2, atrial
fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic
congestive heart failure (NYHA functional classification =II), cerebrovascular
accident including transient ischemic attack, or symptomatic pulmonary embolism.

- Concurrent disease or condition that would make the subject inappropriate for study
participation or any serious medical disorder that would interfere with the subject's

- Contraindications or known hypersensitivity to any of the trial medications or

- Treatment with any investigational agents within 30 days prior to expected start of
trial treatment

- Any GI disorder that may affect absorption of oral medications, such as malabsorption
syndrome or status post major bowel resection

Weitere Angaben zur Studie im WHO-Primärregister


Weitere Angaben zur Studie aus der Datenbank der WHO (ICTRP)


Weitere Informationen zur Studie

Registrationsdatum der Studie


Einschluss der ersten teilnehmenden Person




Wissenschaftlicher Titel (Datenquelle: WHO)

Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Elderly Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer

Studientyp (Datenquelle: WHO)


Design der Studie (Datenquelle: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Phase (Datenquelle: WHO)

Phase 2

Primäre Endpunkte (Datenquelle: WHO)

Pathological complete response (pCR)

Sekundäre Endpunkte (Datenquelle: WHO)

Pathological complete response (pCR) in the breast;Objective response;Frequency of reported adverse events;Rate of breast conserving surgery (BCS)

Kontakt für Auskünfte (Datenquelle: WHO)

Please refer to primary and secondary sponsors


Durchführungsländer (Datenquelle: WHO)

Belgium, France, Italy, Switzerland

Kontakt für weitere Auskünfte zur Studie

Kontakt für allgemeine Auskünfte (Datenquelle: WHO)

Laura Biganzoli, MD;Etienne Brain, MD;Colleen King
USL4 Hospital of Prato, Italy;Institut Curie, Paris, France

Kontakt für wissenschaftliche Auskünfte (Datenquelle: WHO)

Laura Biganzoli, MD;Etienne Brain, MD;Colleen King
USL4 Hospital of Prato, Italy;Institut Curie, Paris, France


Hauptsponsor (Datenquelle: WHO)

International Breast Cancer Study Group

Weitere Sponsoren (Datenquelle : WHO)

Pfizer;Hoffmann-La Roche

Weitere Studienidentifikationsnummern

Secondary ID (Datenquelle: WHO)

2017-005067-40;IBCSG 55-17